Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
A study using the Oncotype DX test showed a relationship between Recurrence Score and chances of breast cancer recurrence and survival in women with estrogen receptor-positive breast cancer that traveled to the lymph nodes in and around the armpit (axillary lymph nodes) who were treated with hormonal therapy and chemotherapy.
NEW YORK (Reuters Health) - Screening women over 65 each year for breast cancer doesn't catch any more early tumors - but it does lead to more false positives - than screening every other year, according to a new study.
NEW YORK (Reuters Health) - A new look at real-world outcomes for women with early-stage breast cancer finds that breast-conserving surgery may offer survival odds that are as good, or even better, than breast removal.
NEW YORK (Reuters Health) - Women carrying BRCA mutations tied to breast and ovarian cancer may hit menopause a few years earlier than other women, according to a new study.
Research shows younger women given pre-surgical, or neoadjuvant, chemotherapy are more likely to have a complete response to that treatment than older women.
An article in the New England Journal of Medicine with updated overall survival results from the international EMILIA study of T-DM1 was published two days following an announcement of accelerated FDA review for the medicine.
Findings from the CONFIRM clinical trial presented at the 2012 San Antonio Breast Cancer Symposium in December showed that increasing the dose of fulvestrant (Faslodex) from 250 mg to 500 mg for women with estrogen receptor-positive metastatic breast cancer increased median overall survival by 4.1 months. Overall survival is the time a person lives from the start of treatment until death from any cause.
Women who waited more than 60 days after a late-stage breast cancer diagnosis were 85 percent more likely to die from the disease than women who began treatment sooner, a retrospective analysis of medical records showed. For this study, late-stage included any cancer that traveled to lymph nodes, regardless of cancer stage.
A follow-up assessment of data from the National Surgical Adjuvant Breast and Bowel Project B-31 (NSABP B-31) clinical trial showed that adding trastuzumab (Herceptin) to combination chemotherapy treatment raises the risk of heart problems, but they are not long-term.
A study of 12,500 women treated for HER2 positive breast cancer showed an association between the use of an anthracycline, trastuzumab (Herceptin) or other chemotherapy and the development of heart failure or cardiomyopathy, disease of the heart muscle. Through analysis of existing medical records, the results support findings of past clinical trials.